↓ Skip to main content

Dove Medical Press

Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial

Overview of attention for article published in Drug Design, Development and Therapy, July 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

policy
1 policy source

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
43 Mendeley
Title
Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial
Published in
Drug Design, Development and Therapy, July 2016
DOI 10.2147/dddt.s110425
Pubmed ID
Authors

Sachio Fushida, Jun Kinoshita, Masahide Kaji, Katsunobu Oyama, Yasuo Hirono, Tomoya Tsukada, Takashi Fujimura, Tetsuo Ohta

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 21%
Other 5 12%
Student > Master 5 12%
Student > Bachelor 4 9%
Student > Doctoral Student 3 7%
Other 3 7%
Unknown 14 33%
Readers by discipline Count As %
Medicine and Dentistry 11 26%
Pharmacology, Toxicology and Pharmaceutical Science 4 9%
Biochemistry, Genetics and Molecular Biology 3 7%
Neuroscience 2 5%
Nursing and Health Professions 1 2%
Other 5 12%
Unknown 17 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2018.
All research outputs
#8,535,472
of 25,374,647 outputs
Outputs from Drug Design, Development and Therapy
#642
of 2,268 outputs
Outputs of similar age
#132,440
of 367,269 outputs
Outputs of similar age from Drug Design, Development and Therapy
#23
of 73 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,269 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.